A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Gemfibrozil (Lopid)

Peroxisome Proliferator Receptor alpha Agonist class · 8 generic manufacturers · 8 ANDAs filed at FDA.

First FDA approval1993-09-27
Generic availableYes · 8 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$21.1M in CY2024 Part D spend1.1M claims · 339K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.103/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.103
Across all dosage forms in distribution.
Highest NADAC
$0.103
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Gemfibrozil used for?

Gemfibrozil is a Peroxisome Proliferator Receptor alpha Agonist medication tracked in Medicare Part D.

Is there a generic for Gemfibrozil?

Yes. 8 ANDAs filed at FDA, 8 generic manufacturers currently shipping.

How much does my plan pay for Gemfibrozil?

Across 329 Part D plans, Gemfibrozil averages $0.103/unit (NADAC). Lowest available: $0.103/unit. Highest in distribution: $0.103/unit.

Is Gemfibrozil on the FDA shortage list?

Gemfibrozil has been discontinued by its manufacturer(s).

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Peroxisome Proliferator Receptor alpha Agonist3 alternatives in D1
01
Fenofibrate
Brand: ANTARA
$0.079Lowest NADAC
26Generic mfrs
$89.1MCY24 Part D spend
Compare →
02
Fenofibric Acid
Peroxisome Proliferator Receptor alpha Agonist
$0.153Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Pioglitazone
Brand: Actos
$0.069Lowest NADAC
11Generic mfrs
$65.9MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (9 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.